



The OptTEST Project – overall conclusions/outcomes and today's programme

Dorthe Raben, OptTEST Coordinator, CHIP, Rigshospitalet,
University of Copenhagen

OptTEST – background and objectives

- Optimising testing and linkage to care for HIV across Europe
- June 2014 September 2017
- The HIV in Europe Initiative
 - Representation from patient advocacy, policy makers, health professionals and European public health institutions
 - Building on previous projects ie the HIDES study (HIV Indicator Conditions across Europe) and support for inclusion of questions on testing in the Stigma Index
- Focus on testing in health care settings and systemic barriers to testing (cost-effectiveness/legal barriers/linkage









- 1) To improve multi-profession, multi-country stakeholder dialogue to develop strategies to improve early diagnosis and care of people with HIV across Europe by 2016.
- 2) To increase knowledge on linkage to and retention in HIV care after diagnosis across geographical and healthcare settings and target groups by 2016.
- 3) Create understanding and suggest evidence-based solutions to provider barriers to testing through pilot implementation of a novel HIV testing strategy (Indicator Condition-guided) in selected European healthcare settings and countries by 2016.
- 4) To assemble and evaluate various existing HIV testing strategies in Europe by 2016.
- 5) To increase knowledge of how stigma and legal barriers to HIV testing affects the uptake of HIV testing and treatment, particularly in most affected groups and regions by 2016.





- 1) To improve multi-profession, multi-country stakeholder dialogue to develop strategies to improve early diagnosis and care of people with HIV across Europe by 2016.
- 2) To increase knowledge on linkage to and retention in HIV care after diagnosis across geographical and healthcare settings and target groups by 2016.
- 3) Create understanding and suggest evidence-based solutions to provider barriers to testing through pilot implementation of a novel HIV testing strategy (Indicator Condition-guided) in selected European healthcare settings and countries by 2016.
- 4) To assemble and evaluate various existing HIV testing strategies in Europe by 2016.
- 5) To increase knowledge of how stigma and legal barriers to HIV testing affects the uptake of HIV testing and treatment, particularly in most affected groups and regions by 2016.





CORE WORK PAC	CORE WORK PACKAGES					
	WP 4	WP 5	WP 6	WP 7		
•	National healthcare authorities	commissioners; Health care decision makers	Health authorities making policy and public spending decisions	PLHIV Networks; Health Care Providers Community Based Organisation		
stake-holders	Healthcare decision makers; Scientific community, Public health bodies like ECDC, WHO, UNAIDS, EMCDDA, etc.) Civil society organisations working on screening and treatment issues	Medical schools, nursing education (including post graduate), specialist training programmes for junior doctors. Special interest groups –Labbased staff IT staff Commercial companies – HIV testing technology, indicator condition/HIV drug companies	Scientific community; Public health bodies like ECDC, WHO, UNAIDS etc. Key populations Civil society actors involved in testing media	Key populations, as defined by WHO; Legal and regulatory authorities		
Key Messages		All individuals have a right to know their HIV status; Indicator condition driven testing is an effective strategy to deliver this; normalising testing and removing potential provider based barriers;		Stigma and Legal /Regulatory barriers negatively impact upon the treatment continuum		
	Disseminate a standard methodology for linkage to care	application of indicator based testing	Disseminate knowledge about cost-effective testing Influence political decisions	Provision of guidance and good practice examples that enable stakeholders to address these issues in country		

OptTEST Meetings







Op/TEST Reception is conjunction with the PM WS Conference on HTV Science (MS 2017) on 23–28 July 2017 or the Polisia sites Congreta in Parts, France

How to increase HIV testing

Launch of tools developed to optimise HIV testing and linkage to care

Time and venue: 20:30 - 22:30h, 25 July 2017, Salan Marcago, Hotel InterContinental, 64 Avenue Morceou, Paris

Background:

The multidisciplinary collaborative EU co-financed project Optimizing testing and tribage to core for HV across Europe - Opt755T - is coming to an end other 3 years of intensive work.

The work has been focused an four areas:

- · Analysing data on Tricage to HV treatment and care and reproving callaborations on national level
- Developing tools to facilitate implementation of indicator con-
- sition (IC) guided HIV enting in primary core and other clinics Modeling the conteffectiveness of different HIV testing op-
- . Developing tools on how best to address stigms and legal and regulatory barriers to HEV resting

The developed tools and examples of their implementation will be presented at this receptors."







Conferences





31 JANUARY-2 FEBRUARY-MALTA



268 participants from 42 countries Next: HepHIV, Romania 2019





























re is a

barriers

nes to

20ih...

Dialogue through social media



www.OptTEST.et










- 1) To improve multi-profession, multi-country stakeholder dialogue to develop strategies to improve early diagnosis and care of people with HIV across Europe by 2016.
- 2) To increase knowledge on linkage to and retention in HIV care after diagnosis across geographical and healthcare settings and target groups by 2016.
- 3) Create understanding and suggest evidence-based solutions to provider barriers to testing through pilot implementation of a novel HIV testing strategy (Indicator Condition-guided) in selected European healthcare settings and countries by 2016.
- 4) To assemble and evaluate various existing HIV testing strategies in Europe by 2016.
- 5) To increase knowledge of how stigma and legal barriers to HIV testing affects the uptake of HIV testing and treatment, particularly in most affected groups and regions by 2016.







Linkage to care: the proportion of patients seen for HIV care (measured by first CD4 count and/or viral load and/or attendance date and/or treatment start date)

within 3 months of diagnosis



the European Union


- 1) To improve multi-profession, multi-country stakeholder dialogue to develop strategies to improve early diagnosis and care of people with HIV across Europe by 2016.
- 2) To increase knowledge on linkage to and retention in HIV care after diagnosis across geographical and healthcare settings and target groups by 2016.
- 3) Create understanding and suggest evidence-based solutions to provider barriers to testing through pilot implementation of a novel HIV testing strategy (Indicator Condition-guided) in selected European healthcare settings and countries by 2016.
- 4) To assemble and evaluate various existing HIV testing strategies in Europe by 2016.
- 5) To increase knowledge of how stigma and legal barriers to HIV testing affects the uptake of HIV testing and treatment, particularly in most affected groups and regions by 2016.






Available online tool to audit/monitor testing (for indicator conditions)

HIDES Audit












All Centers









HIGHLI

Our PDSA (Plan, Do, Study, Act)

LEAFLE

INFORT

Plan:

- to introduce IC testing in Pola
- Do:
 - Emergency Department HIV t
- Study:
 - more patients than expected have gotten used to the new
 - it is easy to see the improver
- Act:
 - From one centre example to a



¿Quieres mejores servicios en cuanto a diagnóstico precoz del VIH en tu centro de atenció primaria??

Dos preguntas en un minuto.

healthcare assistant

ward or discharge:

- 1) To improve multi-profession, multi-country stakeholder dialogue to develop strategies to improve early diagnosis and care of people with HIV across Europe by 2016.
- 2) To increase knowledge on linkage to and retention in HIV care after diagnosis across geographical and healthcare settings and target groups by 2016.
- 3) Create understanding and suggest evidence-based solutions to provider barriers to testing through pilot implementation of a novel HIV testing strategy (Indicator Condition-guided) in selected European healthcare settings and countries by 2016.
- 4) To assemble and evaluate various existing HIV testing strategies in Europe by 2016.
- 5) To increase knowledge of how stigma and legal barriers to HIV testing affects the uptake of HIV testing and treatment, particularly in most affected groups and regions by 2016.





Heat maps considering the most cost-effective

Changes in national HIV testing policies

rotation.

Du kan også holde flere objekter
samlet, så de bliver behandlet som et
enkelt objekt.

Estonia, July 2017

Réévaluation de la stratégie de dépistage de l'infection à VIH en France

- France :
 - High-risk populations
 - MSM should be tested
 - PWID should be tested
 - Migrants form sub-Saha be tested every 12 mon
 - General population: HI entire life should be mattention to
 - Men
 - Regions with a high undiagnosed HIV prevalence

This would be great support for our policy making an practice. We are now developing new HIV guidance which will be hopefully ready by March 2019. So all local data are very important.

OptTES**X**

Mean CD4 at diagnosis

280



- 1) To improve multi-profession, multi-country stakeholder dialogue to develop strategies to improve early diagnosis and care of people with HIV across Europe by 2016.
- 2) To increase knowledge on linkage to and retention in HIV care after diagnosis across geographical and healthcare settings and target groups by 2016.
- 3) Create understanding and suggest evidence-based solutions to provider barriers to testing through pilot implementation of a novel HIV testing strategy (Indicator Condition-guided) in selected European healthcare settings and countries by 2016.
- 4) To assemble and evaluate various existing HIV testing strategies in Europe by 2016.
- 5) To increase knowledge of how stigma and legal barriers to HIV testing affects the uptake of HIV testing and treatment, particularly in most affected groups and regions by 2016.





What is it? ...





This database shows the most common legal and regulatory barriers to HIV testing, linkage to care and treatment access across Europe and in each individual European country, including how they affect particular key populations.



http://legalbarriers.peoplewithhiveurope.org/

The site covers 53 countries of the WHO Europe region

Thanks to all those who contributed – the data is up and live and has gone through several refinements

The site is being updated on an iterative basis



























Tip sheets

Simple principles for effective campaigning on legislative or regulatory change

What types of legal and regulatory barriers are common and how do they damage access?

What are the new testing strategies and where are they working?

How can I identify and verify local barriers to testing and treatment access?

How can I construct or compare a g

How can we do a simple, quick, lov

How and where do I find evidence

How can we build alliances between

How should we present our case to

Influencing at conferences and oth

Questions you should ask yourself Minister

"A community training on addressing punitive and restrictive legal environments hindering early HIV diagnosis and linkage to care drawing on the OptTEST research, interventions and advocacy toolkit on legal and regulatory barriers. Over 90 community activists applied and 25 participants from across Europe were selected to take part in this training" September 2017, Berlin

What can we do when politicians ignore the evidence?



























ent



... and presentations/publications







Countries



Select Language ▼

Presentations & Posters

Tools

2017

Home

JD Kowalska. OptTEST in Poland. OptTEST launch of Tools, 25 July 2017, Paris, in conjunction with IAS 2017 [presentation]

Publications

J Hows. Legal and Regulatory Barriers to testing and treatment. OptTEST launch of Tools, 25 July 2017, Paris, in conjunction with IAS 2017 [presentation]

About

News

L Power. OptTEST barriers toolkit. A toolkit to support challenges to legal and regulatory barriers which hinder access to HIV testing and treatment across Europe.

OptTEST launch of Tools, 25 July 2017, Paris, in conjunction with IAS 2017 [presentation]

A Sullivan. Implementing indicator condition guided HIV testing. OptTEST launch of Tools, 25 July 2017, Paris, in conjunction with IAS 2017 [presentation]

Y Yazdanpanah. From modelling of cost-effectiveness to changes in national HIV testing policies (Estonia, France, Spain). OptTEST launch of Tools, 25 July 2017, Paris, in conjunction with IAS 2017 [presentation]

J del Amo. Coste-efectividad de la realización de la prueba de VIH en atención primaria en España, XVIII National Congress on AIDS and STIs, Sevilla, 22-24 March 2017 [Presentation]

G Mabileau et al. Effectiveness and Cost-Effectiveness of HIV Screening Strategies Across Europe. Poster #1028, CROI 2017. Boston, Massachusetts [Poster]

A Sullivan, Improving Practice in Health Care Settings [Plenary presentation], EU Health Programme Projects' Symposium, Malta, January 2017

S Croxford et al. Factors for delayed linkage to care following HIV diagnosis in the WHO European Region [Plenary presentation & Poster], HepHIV 2017 Conference, Malta, January 2017

V Delpech. Test and link to care: How do we measure our success? [Plenary presentation], HepHIV 2017 Conference, Malta, January 2017

V Hernando et al. Review of specialty guidelines on HIV testing recommendations for HIV indicator conditions in Spain (Poster), HepHIV 2017 Conference, Malta, January 2017






Publications and Presentations

DOI: 10.1111/hiv.12430

© 2016 The Authors, HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association, HIV Medicine (2017), 18, 300-304

SHORT COMMUNICATION



E Lord, 1-* AJ Stockdale, 2-* R Malck, 3 C Rac, 1 Sperle, 5 D Raben, 5 A Freedman, 6 D Churchill, 7 J Lundgren 5 and AK Sullivan4 on behalf of the British Association of Sexual Health HIV (BASHH)/British HIV Association (BHIVA) guideline review group for the Optimising Testing and Linkage to Care for HIV across Europe (OptTEST)* project by HIV in Europe Department of Sexual Health, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK, 3 Imperial College London NHS Healthcare, St Mary's Hospital, London, UK, 4Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, 5Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 6Cardiff University School of Medicine, Cardiff, UK and 7Royal Sussex County Hospital Brighton and Hove UK







Coste-efectividad de la realización de la prueba de VIH en atención primaria en España

MORAL SOCIETY SURRISMOST

Profes

Heph

Shaping the HIV epidemic in Poland proceedings from the first Polish workshop on cascade of care in HIV

turbes Cl. Almedika", Assart Assescraff, Barofea Produk Baroléa", Anna Aberro, Begolomilat Highline Bottski', Nigdilos Aditorotes Settinii (Aditor Hebut)

Tringsted tils finishend Discours is Weinber Total Medical Conveyor of Section 8, 11 Sec. Retired ADS cores Mesters of Study, Related

Albertr with

group of female interpretabilities in force 2007; response Tilly continue of this specific house in manual paid of the direct Daving the treating, amond points of prints were admitted to be consistent? responsible to the state of the (TV witting to assett of a dissay, strating with attractioning wayton (EV) being for each is a deaded inventory across Affaired stocked questions browing the models of 10% persons a reads to come, and no effective AEC continuing to higher degree, and the internation file angle for term

face weeks (CO) Drived, nearly of ours, being, extractored those

Sult Ramon and Witness of conditions print sweet the relatives value (TSA); speed brown e because recommended, beauty retour (APV) prouting people for officer begins 3: [1.5 six office do not of record If I was made and leadily out outs obtain in reading care of new 2005 delicenses, by all, all allows care for each se-

calc, his familia of histocrating balls \$15% and more \$15% countries.















Co-funded by the Health Dwggnam





Effectiveness and Cost-effectiveness of HIV Screening Strategies Across Europe

Guillaume Mabileau^{1,5}, Julia Del Amo^{1,6}, Kristi Büütel¹, A David Paltiel⁶, Lils Lemselu¹, Asunción Disc¹, Jesús Mortin Fernándec^{1,6}, Roche

tale School of Public Health, New Heven, CT, 10A. T Primary Care, National Health System, Modeld Spain; If Nay Joan Corks University, Modeld, Spain; If Medical Process designs

OCERAL of allwins

in the cross of both Treatment as Provention and Infill HV testing has become critical to control the apidismic. Wile evaluated the clinical impact; costs, and cost-effectiveness of tent tenting strategies for both high-risk individuals and the general population in three European countries with different applicatic profites

OptTEST work on legal & regulatory barriers

- Literature review identifying barriers across Europe
- Questionnaire developed from the findings, tested in community settings, distributed by GNP+ and EATG
- · 160 responses from 49 countries
- · Cross-checked with existing data sources
- . Website "Barring The Way To Health" updatable, searchable, cross-comparable
- Also toolkit and report to be published

indicator condition based HIV testing in Estonia

Kristi Rüütel & Liis Lemsalu

fectious Diseases and Drug Monitoring Departmen National Institute for Health Development Estonia

Tervise Arengu Instituut












Meetings and Pilot Activities



OptTEST by HiE Partners































that has received unrestricted funding from:

Platinum partner



Gold partners





Silver partner







Today's programme

• Morning 8:30-14:30

	Sessions: OptTEST and HivEdat
09:15- 10:15	Ways to overcome barriers to HIV testing with new approaches
10:45- 12:00	Tools for innovative testing strategies
13:00- 13:30	Improving linkage to care
13:30- 14:30	Cost-effectiveness and monitoring of HIV testing





Today's programme

• Afternoon 15:00-18:30

	INTEGRATE
15:00- 17:15	Linking experiences from previous and ongoing EU-funded projects to INTEGRATE
17:15- 18:30	Panel Discussion – Moving towards integration of HIV, hepatitis, TB and STIs





THANK YOU